DUBLIN, June 14, 2018 /PRNewswire/ -- Allergan plc
(NYSE: AGN) today announced that Thomas C. Freyman will join
its Board of Directors effective immediately, as part of the
company's ongoing board refreshment process. Mr. Freyman, a former
Executive Vice President of Finance and Administration at Abbott
Laboratories, brings nearly 40 years of healthcare industry and
finance experience to Allergan's Board.
"Since Allergan transitioned from a generics company to a
branded biopharmaceutical company, the Allergan Board has been
actively involved in a refreshment process to update its membership
with the appropriate experience, talent and diversity to more
strongly position Allergan as a premier biopharmaceutical company
and create value for shareholders," said Chris Coughlin, Lead Independent Director. "Mr.
Freyman will become the fourth new Director joining the Allergan
Board in 16 months as we continue to recruit highly-experienced and
qualified members to bring a diversity of perspectives and
strengthen the Board with additional industry, scientific and
financial experience."
Allergan also announced that director Patrick O'Sullivan will retire from the Allergan
Board of Directors in July. Mr. O'Sullivan joined the Board of
Directors in October 2013 following
the Company's acquisition of Warner
Chilcott plc, having served as a member of the Warner
Chilcott Board from 2009. Following the retirement of Mr.
O'Sullivan and the addition of Mr. Freyman, Allergan's Board of
Directors will continue to have 12 members of which 10 are
independent.
"Tom Freyman is an accomplished
healthcare industry executive with a strong track record of
optimizing capital allocation and creating shareholder value,"
said Brent L. Saunders, Chairman and Chief Executive Officer
at Allergan. "Tom has nearly four decades of industry
experience including finance leadership and serving on multiple
public boards, making him a highly valuable addition to the
Allergan Board of Directors."
Mr. Freyman retired from Abbott in 2017, having held various
leadership positions during a period where the company executed a
significant transformation and refocused its business portfolio. He
brings broad-based healthcare experience in two of Allergan's core
therapeutic areas through his tenure at Abbott and his involvement
in its proprietary pharmaceuticals and medical optics businesses.
Most recently, he served as Executive Vice President, Finance and
Administration for Abbott since June
2015. Prior to that, he served as Chief Financial Officer
(CFO) and Executive Vice President, Finance for Abbott. He was
first appointed CFO and Senior Vice President, Finance at Abbott in
2001. Previously, he served as Vice President and Controller of
Abbott's Hospital Products Division and held a number of financial
planning and analysis positions. Prior to joining Abbott, Mr.
Freyman was a certified public accountant at Ernst &
Whinney.
"I am pleased to join Allergan's Board as the company makes
significant progress toward becoming a premier biopharmaceutical
leader," said Mr. Freyman. "I look forward to working with
Allergan's Board and management team to help ensure the company
delivers increased and sustainable long-term value."
Mr. Freyman holds a bachelor's degree in accounting from the
University of Illinois and a master's
degree in management from Northwestern
University. He also serves on the Board of Directors of
Tenneco Inc. and Hanger, Inc., serving on the audit committee of
each of those boards.
In congratulating Mr. O'Sullivan on his retirement, Allergan
Board of Directors Nominating and Corporate Governance Committee
Chair Chris Bodine said, "I know I
reflect the feelings of every member of Allergan's Board of
Directors when I say it has been an honor to serve with
Paddy O'Sullivan. He is a true
professional who brought a deep knowledge of the pharmaceutical
industry to the Allergan Board."
About Allergan plc
Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global
pharmaceutical leader. Allergan is focused on developing,
manufacturing and commercializing branded pharmaceutical, device,
biologic, surgical and regenerative medicine products for patients
around the world.
Allergan markets a portfolio of leading brands and best-in-class
products for the central nervous system, eye care, medical
aesthetics and dermatology, gastroenterology, women's health,
urology and anti-infective therapeutic categories.
Allergan is an industry leader in Open Science, a model of
research and development, which defines our approach to identifying
and developing game-changing ideas and innovation for better
patient care. With this approach, Allergan has built one of the
broadest development pipelines in the pharmaceutical industry.
Allergan's success is powered by our global colleagues'
commitment to being Bold for Life. Together, we build bridges,
power ideas, act fast and drive results for our customers and
patients around the world by always doing what is right.
With commercial operations in approximately 100 countries,
Allergan is committed to working with physicians, healthcare
providers and patients to deliver innovative and meaningful
treatments that help people around the world live longer, healthier
lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in this press release that refer to future
events or other non-historical facts are forward-looking statements
that reflect Allergan's current perspective on existing trends and
information as of the date of this release. Actual results may
differ materially from Allergan's current expectations depending
upon a number of factors affecting Allergan's business. These
factors include, among others, the difficulty of predicting the
timing or outcome of FDA approvals or actions, if any; the impact
of competitive products and pricing; market acceptance of and
continued demand for Allergan's products; the impact of uncertainty
around timing of generic entry related to key products, including
RESTASIS®, on our financial results; risks associated
with divestitures, acquisitions, mergers and joint ventures;
uncertainty associated with financial projections, projected cost
reductions, projected synergies, restructurings, increased costs,
and adverse tax consequences; difficulties or delays in
manufacturing; and other risks and uncertainties detailed in
Allergan's periodic public filings with the Securities and Exchange
Commission, including but not limited to Allergan's Annual Report
on Form 10-K for the year ended December 31,
2017 and Allergan's Quarterly Report on Form 10-Q for the
period ended March 31, 2018. Except
as expressly required by law, Allergan disclaims any intent or
obligation to update these forward-looking statements.
CONTACTS: Allergan:
Investors:
Daphne
Karydas
(862) 261-8006
Karina Calzadilla
(862) 261-7328
Media:
Amy Rose
(862) 289-3072
View original content with
multimedia:http://www.prnewswire.com/news-releases/allergan-continues-active-board-refreshment-process-300666191.html
SOURCE Allergan plc